Cohance Lifesciences Limited reported a consolidated net loss of 241M rupees in Q1FY27, narrowing significantly from a net loss of 489M rupees in the corresponding period of the previous year. The decline in revenue from operations to 4.22B rupees from 5.5B rupees year-on-year was primarily attributed to shipment phasing in the Pharma Contract Development and Manufacturing Organization (CDMO) segment and softer contributions from agrochemicals. Despite the low base, management highlighted tangible indicators of progress, including secured restocking orders for commercial molecules and scheduled deliveries for recently commercialized programs, projecting sequential improvement in Q2FY27 and a return to year-on-year growth from the second half of the fiscal year.

The Board of Directors approved the unaudited financial results on August 5, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Walker Chandiok & Co LLP issued an unmodified limited review report. CFO Himanshu Agarwal confirmed his tenure will continue until September 13, 2026, after which the company will update stakeholders on the succession process.

Financial Performance Highlights

On a standalone basis, net profit fell 97.3% year-on-year to ₹14 crore, while standalone revenue from operations declined 25.6% to ₹359.89 crore. Consolidated gross margins contracted to 71.5% from 73.0% in Q1FY26, driven by product mix shifts and higher freight costs. The consolidated adjusted EBITDA stood at INR92 million (margin of 2.2%), down from higher levels in the prior year, reflecting negative operating leverage and losses from subsidiaries.

Segment Updates and Strategic Initiatives

In the Pharma CDMO segment, revenue declined 38.7% year-on-year due to shipment timing. However, two molecules have moved into commercial supply with deliveries scheduled across Q2FY27 and Q3FY27. A significant restocking order for a commercial molecule affected by inventory destocking in FY26 has been secured, providing visibility for Q4 FY27 and FY28. The API+ segment remained resilient despite a 10.4% year-on-year revenue decline, supported by favorable pricing and product mix. Specialty Chemicals revenue declined 34.7% year-on-year, largely due to expected second-half-weighted phasing in Agrochemicals.

Management announced strategic realignments, including building an integrated nucleic-acid business through Sapala Organics Private Limited. Dr. P.Y. Reddy has agreed to lead this combined nucleic acid business through FY30. Sapala reported 2.5x revenue growth in Q1FY27, contributing INR274 million to consolidated revenue. Conversely, NJ Bio reported an adjusted EBITDA loss of INR328 million, weighing heavily on consolidated profitability.

What the Numbers Show

The divergence between standalone and consolidated performance underscores the transitional challenges following recent acquisitions. While the core standalone business maintained a positive adjusted EBITDA margin of 9.2%, the consolidated entity absorbed significant losses from subsidiaries, particularly NJ Bio. The company maintains a strong liquidity position with consolidated net cash of approximately ₹2,512 million as of June 30, 2026, supporting capital expenditure plans of ₹598 million during the quarter. Additionally, the USFDA completed an inspection of the Pashamylaram facility from July 27 to August 5, 2026, issuing a Form 483 with five observations, none relating to data integrity.

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has uploaded the audio recording of its conference call discussing results for the quarter ended June 30, 2026. The call took place on August 5, 2026, and the recording is now available on the company’s website for investor access. This disclosure ensures transparency regarding management’s commentary on financial performance and operational updates for Q4FY26.

The upload was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This action follows the initial intimation of the conference call results dated July 23, 2026. The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) of the availability of the recording.

Key Details

Sisir Kumar Mishra, Company Secretary & Compliance Officer, signed the disclosure. The communication was addressed to the BSE at Dalal Street, Mumbai, and the NSE at Bandra Kurla Complex, Mumbai. The recording provides stakeholders with direct access to the dialogue between management and analysts, offering clarity on the drivers behind the quarterly figures previously reported.